The life science company Acucort has received a new order for the drug Zeqmelit from its Nordic distribution partner Unimedic Pharma. The order covers the entire Nordic market and has a value of EUR 112,000, which is expected to have a positive effect on earnings in the second quarter of 2026. This is stated in a press release.- The launch of Zeqmelit follows the expected development when a new medicine is launched, which is very positive, says Acucort's CEO Jonas Jönmark.Zeqmelit was launched in Sweden, Norway and Finland in September 2024 and in Denmark during the summer of 2025.